Skip to content

News & updates

Media Coverage

MiRXES and other homegrown firms in virus fight
The fast track to Fortitude Kit for rapid COVID-19 diagnosis
Webinar featuring MiRXES CEO: Perspectives from behind-the-scenes of COVID-19 testing
How MiRXES scaled from cancer to COVID-19
Biotech firms race against time to get around logistical challenges
MiRXES leading the way in microRNA technology
Home-grown firms linked to pandemic work will continue to attract demand, investments
MiRXES’ role in Singapore’s pivot to mass COVID-19 tests
MiRXES is 102nd on Financial Times ranking of Asia-Pacific High Growth Companies
COVID-19 putting MiRXES and Singapore on global deeptech radar
MiRXES heeding the call for COVID-19 testing
MiRXES and Singapore scientists on the front lines of fight against COVID-19
MiRXES — A game changer in microRNA applications
Singapore clears Fortitude Kit SARS-CoV-2 test for clinical use
MiRXES to mass-produce Singapore-developed Fortitude Kit SARS-CoV-2 test kits
MiRXES named Singapore’s fastest growing company in the health sector from 2015-2018
Timely guidance for MiRXES from Pro-Enterprise Panel
GASTROClear blood test for stomach cancer first step to ending all cancer deaths
MiRXES has a real shot at stamping out cancer deaths
Seniors tested for stomach cancer with GASTROClear at free screening in Teck Ghee
MiRXES’ holding company raises US$40M to expand its non-invasive cancer detection technologies in Asia
MiRXES’ holding company clinches $55.03m funding
MiRXES team gets funding to ‘eliminate late-stage cancer’
MiRXES’ holding company launched with US$40m Series A funding
Promising biomedical start-ups in Singapore – MiRXES
MiRXES co-founder Zhou Lihan’s entrepreneurial journey
MiRXES collaborates with Johnson & Johnson to develop miRNA test for lung cancer
MiRXES aims to make cancer tests more accessible
Venturecraft invests in MiRXES